Terms: = Pancreatic cancer AND GPC3, OCI-5, 2719, ENSG00000147257, SGBS, SGB, DGSX, SDYS, P51654, AC002420_1, SGBS1
18 results:
1. Glutamine synthetase and hepatocellular carcinoma.
Jiang J; Hu Y; Fang D; Luo J
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
[TBL] [Abstract] [Full Text] [Related]
2. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
Pang N; Shi J; Qin L; Chen A; Tang Y; Yang H; Huang Y; Wu Q; Li X; He B; Li T; Liang B; Zhang J; Cao B; Liu M; Feng Y; Ye X; Chen X; Wang L; Tian Y; Li H; Li J; Hu H; He J; Hu Y; Zhi C; Tang Z; Gong Y; Xu F; Xu L; Fan W; Zhao M; Chen D; Lian H; Yang L; Li P; Zhang Z
J Hematol Oncol; 2021 Jul; 14(1):118. PubMed ID: 34325726
[TBL] [Abstract] [Full Text] [Related]
3. Phase I studies of peptide vaccine cocktails derived from gpc3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma.
Ikeda M; Okusaka T; Ohno I; Mitsunaga S; Kondo S; Ueno H; Morizane C; Gemmoto K; Suna H; Ushida Y; Furuse J
Immunotherapy; 2021 Apr; 13(5):371-385. PubMed ID: 33525928
[No Abstract] [Full Text] [Related]
4. Co-expression of IL-7 and PH20 promote anti-gpc3 CAR-T tumour suppressor activity in vivo and in vitro.
Xiong X; Xi J; Liu Q; Wang C; Jiang Z; Yue SY; Shi L; Rong Y
Liver Int; 2021 May; 41(5):1033-1043. PubMed ID: 33347692
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms.
Liu JQ; Liao XW; Wang XK; Yang CK; Zhou X; Liu ZQ; Han QF; Fu TH; Zhu GZ; Han CY; Su H; Huang JL; Ruan GT; Yan L; Ye XP; Peng T
BMC Gastroenterol; 2020 Dec; 20(1):415. PubMed ID: 33302876
[TBL] [Abstract] [Full Text] [Related]
6. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.
Taniguchi M; Mizuno S; Yoshikawa T; Fujinami N; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2747-2759. PubMed ID: 32449239
[TBL] [Abstract] [Full Text] [Related]
7. Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment.
Ma W; Zhu D; Li J; Chen X; Xie W; Jiang X; Wu L; Wang G; Xiao Y; Liu Z; Wang F; Li A; Shao D; Dong W; Liu W; Yuan Y
Theranostics; 2020; 10(3):1281-1295. PubMed ID: 31938065
[No Abstract] [Full Text] [Related]
8. [Evaluation of Quality Indicators of Evidence-Based Guidelines Using ADT/GEKID Base Dataset and its Organ-Specific Modules].
Gebauer A; Barlag H; Wesselmann S; Biedenweg L; Weitmann K; Klinkhammer-Schalke M; Hoffmann W
Gesundheitswesen; 2020 Sep; 82(8-09):710-715. PubMed ID: 31842241
[TBL] [Abstract] [Full Text] [Related]
9. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma.
Shimizu Y; Mizuno S; Fujinami N; Suzuki T; Saito K; Konishi M; Takahashi S; Gotohda N; Tada T; Toyoda H; Kumada T; Miura M; Suto K; Yamaji T; Matsuda T; Endo I; Nakatsura T
Cancer Sci; 2020 Feb; 111(2):334-342. PubMed ID: 31774932
[TBL] [Abstract] [Full Text] [Related]
10. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.
Ofuji K; Saito K; Suzuki S; Shimomura M; Shirakawa H; Nobuoka D; Sawada Y; Yoshimura M; Tsuchiya N; Takahashi M; Yoshikawa T; Tada Y; Konishi M; Takahashi S; Gotohda N; Nakamoto Y; Nakatsura T
Oncotarget; 2017 Jun; 8(23):37835-37844. PubMed ID: 28035063
[TBL] [Abstract] [Full Text] [Related]
11. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.
Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y
Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616
[TBL] [Abstract] [Full Text] [Related]
12. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern.
Gao F; Zhu HK; Zhu YB; Shan QN; Ling Q; Wei XY; Xie HY; Zhou L; Xu X; Zheng SS
Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):371-7. PubMed ID: 27498576
[TBL] [Abstract] [Full Text] [Related]
13. Gene expression analysis for evaluation of potential biomarkers in hepatocellular carcinoma.
Hass HG; Jobst J; Scheurlen M; Vogel U; Nehls O
Anticancer Res; 2015 Apr; 35(4):2021-8. PubMed ID: 25862856
[TBL] [Abstract] [Full Text] [Related]
14. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract] [Full Text] [Related]
15. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.
Ikeda M; Ohkawa S; Okusaka T; Mitsunaga S; Kobayashi S; Morizane C; Suzuki I; Yamamoto S; Furuse J
Cancer Sci; 2014 Apr; 105(4):455-62. PubMed ID: 24521523
[TBL] [Abstract] [Full Text] [Related]
16. Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer.
Melson J; Li Y; Cassinotti E; Melnikov A; Boni L; Ai J; Greenspan M; Mobarhan S; Levenson V; Deng Y
Int J Cancer; 2014 Jun; 134(11):2656-62. PubMed ID: 24288256
[TBL] [Abstract] [Full Text] [Related]
17. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms.
Mounajjed T; Zhang L; Wu TT
Hum Pathol; 2013 Apr; 44(4):542-50. PubMed ID: 23079207
[TBL] [Abstract] [Full Text] [Related]
18. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma.
Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH
Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925
[TBL] [Abstract] [Full Text] [Related]
